KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

This study is testing a treatment called KK-LC-1 TCR-T cell therapy — a form of personalized immune cell therapy — in people with certain advanced cancers including gastric (stomach), breast (triple-negative), cervical, and lung cancers. The therapy uses a patient's own immune cells that are re-engineered to recognize and destroy cancer cells carrying a specific protein called KK-LC-1. **You may be eligible if...** - You are 18 or older - You have an advanced cancer (gastric, triple-negative breast, cervical, or lung) that is metastatic - Your tumor tests positive for the KK-LC-1 protein (at least 10% of tumor cells) - You carry a specific genetic marker called HLA-A*01:01 - You have already tried standard cancer treatments - You have measurable disease and adequate organ function - You have no more than 2 treated brain metastases that are stable **You may NOT be eligible if...** - Your tumor does not express KK-LC-1 - You do not have the HLA-A*01:01 genetic marker - You have not received prior standard therapies - You have active, untreated brain metastases Talk to your doctor to see if this trial is right for you.